

Application No. 10/699,517
Amendment dated February 24, 2005
Reply to Office Action of February 2, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) A method of preventing or treating a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprising administering an effective regime of an agent that induces an immunogenic response against alpha-synuclein to a patient.
2. (Original) The method of claim 1, wherein the immunogenic response comprises antibodies to alpha synuclein.
3. (Original) The method of claim 1, wherein the agent is alpha-synuclein.
4. (Original) The method of claim 1, wherein the agent is an immunogenic fragment of alpha-synuclein.
5. (Original) The method of claim 4, wherein the immunogenic fragment is amino acid residue 35-65 of alpha-synuclein (SEQ ID NO: 1).
6. (Original) The method of claim 4, wherein the immunogenic fragment comprises amino acid residues 130-140 of alpha-synuclein (SEQ ID NO: 1) and has fewer than 40 amino acids total.
7. (Original) The method of claim 4, wherein the C-terminal amino acid of the fragment is the C-terminal amino acid of alpha-synuclein.
8. (Original) The method of claim 1, further comprising determining that a patient is suffering from or at risk of a disease characterized by Lewy bodies, wherein the determining step occurs before the administration step.

Application No. 10/699,517
Amendment dated February 24, 2005
Reply to Office Action of February 2, 2005

9. (Original) The method of claim 8, wherein the determining step determines that a patient is suffering from a clinical symptom of a disease characterized by Lewy bodies.

10. (Original) The method of claim 8 or 9, further comprising determining the patient is free of clinical symptoms of a disease characterized by amyloid deposits of A β .

11. (Original) The method of claim 3, wherein the alpha-synuclein is administered with an adjuvant.

12. (Original) The method of claim 4, wherein the immunogenic alpha-synuclein fragment is administered with an adjuvant.

13. (Original) The method of claim 3, wherein the alpha-synuclein is linked to a carrier molecule to form a conjugate.

14. (Original) The method of claim 13, wherein the alpha-synuclein is linked to the carrier molecule at the N-terminus of the alpha-synuclein.

15. (Original) The method of claim 4, wherein the immunogenic alpha-synuclein fragment is linked to a carrier molecule to form a conjugate.

16. (Original) The method of claim 15, wherein the immunogenic alpha-synuclein fragment is linked to the carrier molecule at the N-terminus of the immunogenic alpha-synuclein fragment.

17. (Original) The method of claim 1, wherein the agent is an antibody to alpha-synuclein or a fragment thereof.

18. (Original) The method of claim 17, wherein the antibody is a humanized antibody.

19. (Original) The method of claim 17, wherein the antibody is human

Application No. 10/699,517
Amendment dated February 24, 2005
Reply to Office Action of February 2, 2005

20. (Original) The method of claim 18 or 19, wherein the antibody is an antibody of human IgG1 isotype.

21. (Original) The method of claim 17, wherein the antibody is a monoclonal antibody.

22. (Original) The method of claims 17, wherein the antibody is a polyclonal antibody.

23. (Original) The method of claim 17, wherein the antibody is prepared from a human immunized with alpha-synuclein peptide.

24. (Original) The method of claim 23, wherein the human is the patient to be treated with antibody.

25. (Original) The method of claim 17 or 18, wherein the antibody is administered with a pharmaceutical carrier as a pharmaceutical composition.

26. (Original) The method of claim 17, wherein the antibody is administered at a dosage of 0.0001 to 100 mg/kg, preferably, at least 1 mg/kg body weight antibody.

27. (Original) The method of claim 17, wherein the antibody is administered in multiple dosages over a prolonged period, for example, of at least six months.

28. (Original) The method of claim 17, wherein the antibody is administered as a sustained release composition.

29. (Original) The method of claim 17, wherein the antibody is administered intraperitoneally, orally, subcutaneously, intracranially, intramuscularly, topically, intranasally or intravenously.

30. (Original) The method of claim 17, wherein the antibody is administered by administering a polynucleotide encoding at least one antibody chain to the patient.

Application No. 10/699,517
Amendment dated February 24, 2005
Reply to Office Action of February 2, 2005

41. (Currently Amended) A method of ~~preventing or therapeutically treating a~~
patient suffering from a disease characterized by Lewy bodies or alpha-synuclein aggregation in
the brain, the method comprising

administering to the patient an effective regime of an agent that induces an
immunogenic response against A β to-a in the patient and thereby therapeutically treating the
disease.

42. (Original) The method of claim 41, wherein the agent is A β or an
immunogenic fragment thereof.

43. (Original) The method of claim 41, wherein the agent is an antibody to A β
or a fragment thereof.

44. (Currently Amended) A method of ~~preventing or therapeutically treating a~~
patient suffering from a disease characterized by Lewy bodies or alpha synuclein deposits in the
brain, comprising

administering to the patient an effective regime of an agent that induces an
immunogenic response against alpha-synuclein and an agent that induces an immunogenic
response against A β to-a in the patient and thereby therapeutically treating the disease.

45. (Currently Amended) The method of claim ~~1~~ or 41, wherein the agent is
administered peripherally.

46. (Currently Amended) The method of claim ~~1~~ or 41, wherein the effective
regime comprises administering multiple dosages over a period of at least six months.

47. (Currently Amended) The method of claim ~~1~~ or 41, wherein the patient is
asymptomatic.

48. (Currently Amended) The method of claim ~~1~~ or 41, wherein the patient
has a risk factor for the disease.

Application No. 10/699,517
Amendment dated February 24, 2005
Reply to Office Action of February 2, 2005

49. (Canceled)

50. (Currently Amended) The method of claim 49-41, wherein the disease is Parkinson's disease.

51. (Original) The method of claim 50, wherein the patient has Parkinson's disease and the administering results in improvement in a sign or symptom of Parkinson's disease.

52. (Original) The method of claim 50, wherein the patient has Parkinson's disease, and the administering improves motor characteristics of the patient.

53. (Currently Amended) The method of claim 49-41, further comprising monitoring a sign or symptom of Parkinson's disease in the patient.

54. (Currently Amended) The method of claim 49-41, wherein the patient is free of Alzheimer's disease.

55. (Original) The method of claim 54, wherein the patient is free of Alzheimer's disease and has no risk factors thereof.

56. (Original) A pharmaceutical composition comprising an agent effective to induce an immunogenic response against a component of a Lewy body in a patient.

57. (Original) The pharmaceutical composition of claim 56, wherein the agent is an antibody specific for a component of a Lewy body.

58. (Original) The pharmaceutical composition of claim 56, wherein the agent is alpha-synuclein, an immunogenic alpha-synuclein fragment, 6CHC-1, or an immunogenic 6CHC-1 fragment.

59. (Original) The pharmaceutical composition of claim 56, wherein the agent is an immunogenic alpha-synuclein fragment.

Application No. 10/699,517
Amendment dated February 24, 2005
Reply to Office Action of February 2, 2005

60. (Original) The pharmaceutical composition of claim 59, wherein the immunogenic alpha-synuclein fragment is NAC.

61. (Original) The pharmaceutical composition of claim 56, further comprising a pharmaceutically acceptable adjuvant.

62. (Original) A method of screening an antibody for activity in preventing or treating a disease associated with Lewy bodies, comprising
contacting a neuronal cell expressing synuclein with the antibody;
determining whether the contacting reduces synuclein deposits in the cells compared with a control cells not contacted with the antibody.

63. (Original) A method of screening an antibody for activity in treating or preventing a Lewy body disease in the brain of a patient, comprising contacting the antibody with a polypeptide comprising at least five contiguous amino acids of alpha-synuclein; and
determining whether the antibody specifically binds to the polypeptide, specific binding providing an indication that the antibody has activity in treating the disease.

64. (Original) A method of screening an agent to determine whether the agent has activity useful in treating a disease characterized by Lewy Bodies, comprising
contacting the agent with a transgenic nonhuman animal disposed to develop a characteristic of a Lewy Body disease with the agent;
determining whether the agent affects the extent or rate of development of the characteristic relative to a control transgenic nonhuman animal;
wherein the agent is an immunogenic fragment of alpha synuclein or an antibody to alpha synuclein.

65. (Original) The method of claim 64, wherein the transgenic nonhuman animal comprises a transgene expressing alpha-synuclein.

Application No. 10/699,517
Amendment dated February 24, 2005
Reply to Office Action of February 2, 2005

66. (Original) The method of claim 65, wherein the alpha synuclein transgene is full length alpha synuclein.

67. (Original) The method of claim 64, wherein the transgenic nonhuman animal further comprises a transgene expressing amyloid precursor protein.

68. (Original) The method of claim 36, wherein the administering of the agent inducing an immunogenic response to alpha-synuclein and the agent inducing an immunogenic response to A β is simultaneous, separate, or sequential.

69. (Original) The pharmaceutical composition of claims 56, wherein the agent is linked to a carrier molecule to form a conjugate.

70. (Original) The pharmaceutical composition of claims 56, further comprising an agent effective to induce an immunogenic response against A β .

71. (New) A method of prophylactically treating a patient susceptible to a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprising
administering to the patient an effective regime of an agent that induces an immunogenic response against A β in the patient and thereby effecting prophylaxis of the disease.

72. (New) The method of claim 71, wherein the agent is A β or an immunogenic fragment thereof.

73. (New) The method of claim 71, wherein the agent is an antibody to A β or a fragment thereof.

74. (New) A method of prophylactically treating a patient susceptible to a disease characterized by Lewy bodies or alpha synuclein deposits in the brain, comprising

Application No. 10/699,517
Amendment dated February 24, 2005
Reply to Office Action of February 2, 2005

administering to the patient an effective regime of an agent that induces an immunogenic response against alpha-synuclein and an agent that induces an immunogenic response against A β in the patient and thereby effecting prophylaxis of the disease.

75. (New) The method of claim 71, wherein the agent is administered peripherally.

76. (New) The method of claim 71, wherein the effective regime comprises administering multiple dosages over a period of at least six months.

77. (New) The method of claim 71, wherein the patient is asymptomatic.

78. (New) The method of claim 77, wherein the patient has a risk factor for the disease.

79. (New) The method of claim 71, wherein the patient is free of Alzheimer's disease.

80. (New) The method of claim 79, wherein the patient is free of Alzheimer's disease and has no risk factors thereof.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.